Clinical nuclear medicine · 2022
Diagnostic Performance of 18F-FDG PET/CT for Lymph Node Staging in Penile Cancer.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Sang Woo, Kim Seong-Jang
Аннотация
OBJECTIVE: The purpose of the current study was to evaluate the diagnostic accuracies of 18F-FDG PET/CT for detection of lymph node (LN) metastasis in penile cancer (PeCA) patients through a systematic review and meta-analysis.
PATIENTS AND METHODS: The PubMed, Cochrane database, and Embase database, from the earliest available date of indexing through August 31, 2021, were searched for studies evaluating diagnostic performance of 18F-FDG PET/CT for detection of metastatic LN in PeCA patients. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-, respectively), and constructed summary receiver operating characteristic curves.
RESULTS: Across 12 studies (479 patients), the pooled sensitivity of 18F-FDG PET/CT was 0.87 (95% confidence interval [CI], 0.79-0.92) and the pooled specificity was 0.88 (95% CI, 0.79-0.93). Likelihood ratio syntheses gave an overall LR+ of 7.2 (95% CI, 3.9-13.1) and LR- of 0.15 (95% CI, 0.1-0.24). The pooled diagnostic odds ratio was 47 (95% CI, 19-116). In meta-regression analysis, no variable was the source of the study heterogeneity.
CONCLUSIONS: 18F-FDG PET/CT showed a good diagnostic performances for detection of metastatic LN in PeCA patients. Also, 18F-FDG PET/CT revealed similar diagnostic accuracy for detection of inguinal and pelvic LN metastasis in PeCA patients.
PATIENTS AND METHODS: The PubMed, Cochrane database, and Embase database, from the earliest available date of indexing through August 31, 2021, were searched for studies evaluating diagnostic performance of 18F-FDG PET/CT for detection of metastatic LN in PeCA patients. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-, respectively), and constructed summary receiver operating characteristic curves.
RESULTS: Across 12 studies (479 patients), the pooled sensitivity of 18F-FDG PET/CT was 0.87 (95% confidence interval [CI], 0.79-0.92) and the pooled specificity was 0.88 (95% CI, 0.79-0.93). Likelihood ratio syntheses gave an overall LR+ of 7.2 (95% CI, 3.9-13.1) and LR- of 0.15 (95% CI, 0.1-0.24). The pooled diagnostic odds ratio was 47 (95% CI, 19-116). In meta-regression analysis, no variable was the source of the study heterogeneity.
CONCLUSIONS: 18F-FDG PET/CT showed a good diagnostic performances for detection of metastatic LN in PeCA patients. Also, 18F-FDG PET/CT revealed similar diagnostic accuracy for detection of inguinal and pelvic LN metastasis in PeCA patients.